Cargando…
Nanoparticle pre-treatment for enhancing the survival and activation of pulmonary macrophage transplant
Despite recent clinical successes of chimeric antigen receptor T cell therapies in treating liquid cancers, many lingering challenges stand in the way of therapeutic translation to broader types of malignancies. Macrophages have been proposed as alternatives to T cells given macrophages’ advantages...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238309/ https://www.ncbi.nlm.nih.gov/pubmed/36917409 http://dx.doi.org/10.1007/s13346-023-01319-6 |
_version_ | 1785053267011567616 |
---|---|
author | Jarai, Bader M. Bomb, Kartik Fromen, Catherine A. |
author_facet | Jarai, Bader M. Bomb, Kartik Fromen, Catherine A. |
author_sort | Jarai, Bader M. |
collection | PubMed |
description | Despite recent clinical successes of chimeric antigen receptor T cell therapies in treating liquid cancers, many lingering challenges stand in the way of therapeutic translation to broader types of malignancies. Macrophages have been proposed as alternatives to T cells given macrophages’ advantages in promoting tumor infiltration, acquiring diverse antigens, and possessing the ability to continuously stimulate adaptive responses. However, the poor survival of macrophages upon transplantation in addition to transient anti-tumor phenotypical states have been major obstacles standing in the way of macrophage-based cell therapies. Given recent discoveries of nanoparticle strategies in improving macrophage survival and promoting phenotype retention, we herein report the ability to extend the survival and phenotype of macrophage transplants in murine lungs via pre-treatment with nanoparticles of varying degradation rates. Macrophages pre-treated with 100 µg/ml dose of poly(ethylene glycol) diacrylate nanoparticle formulations improve pulmonary macrophage transplant survival over untreated cells beyond 7 days, where degradable nanoparticle formulations result in over a 50% increase in retention of transplanted cell counts relative to untreated cells. Furthermore, pre-treated macrophages more efficiently retain an imposed pro-inflammatory-like polarization state following transplantation out to 7 days compared to macrophages pre-treated with a classical pro-inflammatory stimulus, interferon-gamma, where CD86 costimulatory molecule expression is greater than 150% higher in pre-treated macrophage transplants compared to untreated counterparts. These findings provide an avenue for a major improvement in the lifespan and efficacy of macrophage-based cell therapies and have broader implications to other phagocyte-based cellular therapeutics and administration routes. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13346-023-01319-6. |
format | Online Article Text |
id | pubmed-10238309 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-102383092023-06-04 Nanoparticle pre-treatment for enhancing the survival and activation of pulmonary macrophage transplant Jarai, Bader M. Bomb, Kartik Fromen, Catherine A. Drug Deliv Transl Res Original Article Despite recent clinical successes of chimeric antigen receptor T cell therapies in treating liquid cancers, many lingering challenges stand in the way of therapeutic translation to broader types of malignancies. Macrophages have been proposed as alternatives to T cells given macrophages’ advantages in promoting tumor infiltration, acquiring diverse antigens, and possessing the ability to continuously stimulate adaptive responses. However, the poor survival of macrophages upon transplantation in addition to transient anti-tumor phenotypical states have been major obstacles standing in the way of macrophage-based cell therapies. Given recent discoveries of nanoparticle strategies in improving macrophage survival and promoting phenotype retention, we herein report the ability to extend the survival and phenotype of macrophage transplants in murine lungs via pre-treatment with nanoparticles of varying degradation rates. Macrophages pre-treated with 100 µg/ml dose of poly(ethylene glycol) diacrylate nanoparticle formulations improve pulmonary macrophage transplant survival over untreated cells beyond 7 days, where degradable nanoparticle formulations result in over a 50% increase in retention of transplanted cell counts relative to untreated cells. Furthermore, pre-treated macrophages more efficiently retain an imposed pro-inflammatory-like polarization state following transplantation out to 7 days compared to macrophages pre-treated with a classical pro-inflammatory stimulus, interferon-gamma, where CD86 costimulatory molecule expression is greater than 150% higher in pre-treated macrophage transplants compared to untreated counterparts. These findings provide an avenue for a major improvement in the lifespan and efficacy of macrophage-based cell therapies and have broader implications to other phagocyte-based cellular therapeutics and administration routes. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13346-023-01319-6. Springer US 2023-03-14 2023 /pmc/articles/PMC10238309/ /pubmed/36917409 http://dx.doi.org/10.1007/s13346-023-01319-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Jarai, Bader M. Bomb, Kartik Fromen, Catherine A. Nanoparticle pre-treatment for enhancing the survival and activation of pulmonary macrophage transplant |
title | Nanoparticle pre-treatment for enhancing the survival and activation of pulmonary macrophage transplant |
title_full | Nanoparticle pre-treatment for enhancing the survival and activation of pulmonary macrophage transplant |
title_fullStr | Nanoparticle pre-treatment for enhancing the survival and activation of pulmonary macrophage transplant |
title_full_unstemmed | Nanoparticle pre-treatment for enhancing the survival and activation of pulmonary macrophage transplant |
title_short | Nanoparticle pre-treatment for enhancing the survival and activation of pulmonary macrophage transplant |
title_sort | nanoparticle pre-treatment for enhancing the survival and activation of pulmonary macrophage transplant |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238309/ https://www.ncbi.nlm.nih.gov/pubmed/36917409 http://dx.doi.org/10.1007/s13346-023-01319-6 |
work_keys_str_mv | AT jaraibaderm nanoparticlepretreatmentforenhancingthesurvivalandactivationofpulmonarymacrophagetransplant AT bombkartik nanoparticlepretreatmentforenhancingthesurvivalandactivationofpulmonarymacrophagetransplant AT fromencatherinea nanoparticlepretreatmentforenhancingthesurvivalandactivationofpulmonarymacrophagetransplant |